Close Menu

NEW YORK (GenomeWeb) – Cedars-Sinai plans this fall to open a research and clinical laboratory focused on validating and implementing disease biomarkers.

Called the Cedars-Sinai Precision Biomarker Lab, the facility will be mass spectrometry-focused and will comprise both a research service contract lab for building and validating protein biomarker tests as well as a CAP-accredited, CLIA-certified lab for offering protein biomarker tests clinically, said Jennifer Van Eyk, codirector of the hospital's Precision Medicine Initiative.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One gene regulates hundreds of others to influence facial development, according to New Scientist.

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.